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inducible virus replication upon forskolin and heat stress
(HS) treatment. In this research, We further characterized the

Al—Saadi SA, Gross P, Wildy P (1988). Herpes simplex virus

ND-PC12
model Withcells
respect
are non-permissive
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NEURONAL CELL MODEL AND METHODS
OF USE THEREOF

al, 1996; Smith et al, 1992; Smith et al, 1994), (ii) lack of
virus production folloWing removal of the inhibitory agent,

CROSS REFERENCE TO RELATED
APPLICATION

(Wilcox and Johnson, 1988) (iii) the presence of latency
associated transcripts (LATs) (Doerig et al, 1991; Smith et
al, 1994), (iv) impaired reactivation of thymidine kinase
negative virus (Wilcox et al, 1992), and (v) inducible

The present application claims the bene?t of priority to
US. Provisional Application No. 60/243,701, ?led Oct. 27,

reactivation (Halford et al, 1996; Moriya et al, 1994; Smith

2000. The contents of this provisional application are incor

porated herein by reference in its entirety.
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FIELD OF THE INVENTION

in?uence reactivation of virus.

The present invention relates, in general, to neurally
differentiated cells infected With viruses in a manner that

supports a long-term non-productive infection for experi
mentation concerning the reactivation, induction, suppress
ing of virus latency.

15

BACKGROUND OF THE INVENTION

Herpes simpleX virus types 1 and 2 (HSV-1 and -2) are

Accordingly, development of cell culture models With
neuronal characteristics that lack the restrictive require
ments of tissue culture models Would be advantageous for
understanding the molecular mechanisms of the
establishment, maintenance and reactivation stages of HSV
latency. Cell culture models also alloW for an unlimited
supply of a de?ned host cell and the ability to manipulate

genetic material.

alphaherpesviruses With similar, but unique molecular (Kieff
et. al., 1971, 1972), biological and clinical features
(revieWed in Whitley, 1996). The genomes are approXi
mately 150 kb in siZe and each contains corresponding sets
of 74 genes (Dolan et al, 1998). Both viruses infect
epithelium, With HSV-1 having a predilection for orofacial

et al, 1992; WilcoX and Johnson, 1988; WilcoX and Johnson
1987; WilcoX et al, 1990). Nevertheless, tissue culture
models have their draWbacks, preparation of dissected gan
glia is inconvenient, material is limited, animal use is
required, and aXotomy introduces traumatic factors that

25

Over the past 25 years, cell culture systems using
blast cultures (Harris and Preston, 1991; Jamieson
1995; O’Neill, 1977; O’Neill et al, 1972; Russell et al,
Scheck et al, 1989; Wigdahl et al, 1982a; Wigdahl

?bro
et al,

1987;
et al,

1982b; Wigdahl et al, 1983) and lymphocytes (Hammer et
al, 1981; Youssou?an et al, 1982) have enabled the study of

sites and HSV-2 preferentially infecting genital surfaces.

HSV-1 during a latent-like state. These models, hoWever

During the primary infection, HSV invades local nerve
endings and travels to sensory ganglia Where it can coloniZe
neuronal nuclei and establish a latent state (Hill et al, 1972,
Stevens and Cook, 1971). Reactivation of HSV from latency

inhibitors such as anti-viral agents, inhibitory temperatures,

required loW input multiplicities and/or the use of replication
or the use of a mutant virus, to prevent virus production. A

cell line that has neural morphology and physiology, can

occurs intermittently as a result of stressful stimuli (e.g.,

survive infection and permit viral production, alloW estab
lishment of a long term nonproductive viral infection, and

trauma and heat). Reactivated viruses are responsible for

causing recurrent epithelial infections that can occur in up to 35 support virus in a state suitable for reactivation studies
89% of infected individuals (Benedetti, et. al. 1994).
Would be more desirable.

The lack of a universally accepted neural cell culture

More recently, it has been reported that neurally

model that supports HSV latency, in particular, HSV-2,

differentiated PC12 (ND-PC12) cells can harbor HSV-1 in a

restricts our understanding of the molecular events involved

quiescent, yet reversible state (Danaher et. al., 1999a). These
quiescently infected ND-PC12 cultures (QIF-PC12) dem

in reactivation from latency. Although animal models repro
duce certain aspects of HSV-2 latency in humans (Al-Saadi
et al, 1988; Bourne et al, 1994; Croen et al, 1991; Krause et
al, 1995; Kurata et al, 1978; MacLean et al, 1991; Martin
and Suzuki, 1989; Mitchell et al, 1990; Stanberry et al, 1982;
Stephanopoulos et al, 1988; Wang et al, 1997; YoshikaWa et
al, 1996), limitations in these models make interpretation of
reactivation data challenging. Animal models limitations
include:

onstrate forskolin- and heat stress (HS)-inducible virus

production in a high percentage (50—100%) of cultures for
up to 8 Weeks after infection, Whereas mock-induced cul
tures maintain the quiescent viral state in the majority of
45

latency and reactivation events that are in?u

enced by viral strains With different primary groWth
phenotypes, (ii) the limited number of neurons latently
infected in animal models (Bloom et al, 1996; Hill et al,
1996; Maggioncalda et al, 1996; Mehta et al, 1995;
Ramakrishnan 1994; SaWtell, 1997; SaWtell et al, 1998;

al, 1989; Kondo et al, 1990; O’Neill, 1977; O’Neill et al,
1972; Russell et al, 1987; Russell and Preston, 1986;
Wigdahl et al, 1981; WilcoX and Johnson, 1988; WilcoX et
al, 1990; Yura et al, 1986).
The present application demonstrates that ND-PC12 cells

Thompson and SaWtell, 1997), and (iii) inaccurate quanti
tation of reactivation events When measuring virus produc

infected cultures (Danaher et al, 1999b). In contrast to these
cell culture models, the present invention, hoWever, does not
require antiviral conditions to maintain and/or establish the
latent-like state (Colberg-Poley et al, 1979, 1981; Harris et

permit establishment of an HSV-2 quiescent state, like
55

HSV-1, folloWing transient acycloguanosine (ACV) treat

tion at the recurrent site as a result of in?uences of transport,

ment. Unlike HSV-1, hoWever, antiviral conditions are not

replication in epithelium, and the immune response.

required for the establishment of the HSV-2 quiescent state.
In addition, the present invention discloses quiescent cul

In response to these limitations, tissue and cell culture
models of HSV-2 latency have been developed in an attempt
to overcome limitations of animal models. A major advan
tage of tissue and cell culture models includes the ability to
observe virus at the single cell level Without the overlay of
immunological events that modulate the eventual appear
ance of virus in the host. In addition, tissue culture models

derived from neuronal and sympathetic ganglia have prop
erties of the in vivo system including:
restricted tran
scription of the HSV genome (Doerig et al, 1991; Halford et

tures in the presence of Vero cells, and the presence of Vero

cells enhances the sensitivity to detect HSV-2 produced

spontaneously and folloWing induction (i.e., forskolin and
HS treatment). Thus, the present invention demonstrates that
ND-PC 12 cells can harbor HSV-2, like HSV-1, in a cryptic

and non-productive state that is reversible, and this model
65

has appealing features for studying gene induction during
the establishment and maintenance of virus latency and the
activation of HSV-2 from a nonproductive state.

US 6,573,041 B2
3
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SUMMARY OF THE INVENTION

a container; and incubating said container With an antiviral
reagent for a time necessary to accomplish quiescence of

Aprimary object of the present application is to provide

viral activity; and removing said antiviral agent from said

neurally-differentiated cells infected With viruses in a man

container. Preferred such methods are those Wherein the

ner that supports a long-term non-productive infection for

neurotropic virus is a neurotropic herpes virus. More pre
ferred are those methods Wherein the neurotropic herpes
virus is a human herpes simplex 2 virus. HoWever, those
methods Wherein the neurotropic virus is selected from the
group consisting essentially of varicella Zoster viruses,

experimentation. Another object of the present invention
also provides a cell culture research model for HSV-2

quiescent infection in ND-PC12 cells to investigate quies
cent and reactivation properties of HSV-2. This model
represents an improvement over existing cell culture models

for HSV-1. Advantages of this quiescently infected PC12
cell culture model include: (1) establishment and mainte

10

epstein barr viruses, hepatitis viruses, coronaviruses, cox
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses,

nance of a HSV-2 quiescent infection in a high proportion of
PC12 cell cultures With and Without the transient use of ACV

(acyclovir); (2) the ability to produce HSV-2 from a quies
cent state in response to forskolin and HS treatment for at

15

lest 4 Weeks post infection; and (3) the ability to discriminate
betWeen quiescence, spontaneous reactivation and inducible
reactivation using a range of multiplicities of infection
(MOIs). Thereby, these enhanced features of the invention
enable analysis of the establishment and maintenance of

togaviruses, and rhinoviruses are also preferred. Methods
Wherein the neurotropic herpes virus is a human herpes
simplex 2 virus and the antiviral agent is acyclovir are
preferred, especially those methods Wherein said container
is incubated With an antiviral composition for approximately
?ve (5) to tWelve (12) days, more especially methods
Wherein said container is incubated at a temperature less

than 40 degrees Celsius (40° C.), and most especially
Wherein said serum free medium alloWs for constant cell

latency and the reactivation events of a cryptic HSV genome
at the single neural cell level in vitro.

Accordingly, additional objects of the present invention
provide for methods of establishing quiescently-infected
PC12 cells, reactivating quiescent virus, determining the

polyoma viruses, measles viruses, human immunode?ciency

viruses, papillomaviruses, adenoviruses, cytomegaloviruses,

25

density and imparts neural characteristics to said cells.
Importantly, also provided are methods of establishing
quiescently-infected neural cells Without using an antiviral
reagent, comprising introducing a neurotropic virus to

ability of a test reagent to suppress and/or induce virus

neurally-differentiated and viable PC12 cells in a serum-free

reactivation, eliciting phenotypic change in a PC12 cell,

medium; replenishing the serum-free medium after intro
duction of the neurotropic virus to maintain acceptable cell

determining the susceptibility to reactivation of a person

viability. Preferably, the medium is replenished daily for
three (3) days, and thereafter, every tWo (2) to three (3) days
until experimentation.

infected With a quiescent virus, identifying nucleic acid
molecules and/or proteins involved in virus reactivation,
identifying the origins of DNA replication important to virus
reactivation, screening an altered virus’ ability to be
reactivated, determining the ability of a non-neurotropic
virus to become quiescent and/or reactivatable, and a
method of determining a reagent’s ability to inhibit estab
lishment of quiescent viral infection.

Also provided are methods of reactivating a quiescent

virus from neural cell, comprising: introducing a reactivator
35

to any of the herein described quiescently-infected neural
cells.
Also provided are methods for determining the ability of
a test reagent to suppress virus reactivation from a

Additional objects and attendant advantages of the present
invention Will be set forth, in part, in the description that
folloWs, or may be learned from practicing or using the
present invention. The objects and advantages may be

test reagent to a quiescently-infected neural cell described

realiZed and attained by means of the instrumentalities and

determining if reactivation has been suppressed.
Also provided are methods for determining the ability of

combinations particularly recited in the appended claims. It
is to be understood that the foregoing general description
and the folloWing detailed description are exemplary and

quiescently-infected neural cell, comprising introducing a
herein; and introducing to said neural cell a reactivator; and

a test reagent to induce virus reactivation in a neural cell,
45

infected neural cell described herein; and determining if

explanatory only and are not to be vieWed as being restric
tive of the invention, as claimed.

reactivation has been induced.

Also provided are methods for determining the ability of

The present invention provides, inter alia, neural cells

a test reagent to establish virus latency in a neural cell,
comprising introducing a test reagent to a quiescently

comprising a PC12 cell quiescently infected With a neuro

tropic virus. Preferred quiescently-infected neural cells are
those Wherein the neurotropic virus is a neurotropic herpes
virus. More preferred are quiescently-infected neural cells
Wherein the neurotropic virus is a neurotropic human herpes
virus. More preferred are quiescently-infected neural cells
Wherein the neurotropic herpes virus is a human herpes

infected neural cell described herein; and determining if
latency has been induced.
Also provided are methods for determining the ability of
a test reagent to inhibit establishment of a quiescent viral
55

simplex 2 virus. HoWever, those quiescently-infected neural
cells Wherein the neurotropic virus is selected from the

viruses, papillomaviruses, adenoviruses, cytomegaloviruses,

virus to neurally-differentiated and viable PC12 cells in a

serum-free medium, said differentiated PC12 cells being in

infection, comprising introducing a virus to differentiated
and viable PC12 cells; replenishing the serum-free medium
after introduction of the non-neurotropic virus to maintain

acceptable cell viability. Preferably, the medium is replen
ished daily for three (3) days, and thereafter, every tWo (2)
to three (3) days until experimentation.
Also provided are methods for eliciting phenotypic

group consisting essentially of varicella Zoster viruses,

polyoma viruses, measles viruses, human immunode?ciency
epstein barr viruses, hepatitis viruses, coronaviruses, cox
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses,
togaviruses, and rhinoviruses, are also preferred.
Also provided are methods of establishing quiescently
infected neural cells, comprising introducing a neurotropic

comprising introducing a test reagent to a quiescently

change in a neural cell, introducing a reactivator to a

quiescently-infected neural cell described herein, and elic
iting a phenotypic change in said neural cell. Preferred are
65

such methods Wherein said phenotypic change is selected

from the group consisting of synthesis of myelin, synthesis
of neurotransmitter, cell death, and viral shedding.

US 6,573,041 B2
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Also provided are methods for determining the suscepti

“isolated” means physically removed from a form found

bility of a person infected With a quiescent virus to reacti

in nature. For instance, Whole cells, a crude cell extract,

vation by a reagent, comprising introducing a reactivator to
a quiescently-infected neural cell described herein, Wherein

puri?ed virus, molecularly engineered virus, or arti?
cial virus Would be “isolated” virus.
“neurotropic virus” means any virus Which is capable of

the neurotropic virus is a strain isolated from a person

infected With said neurotropic virus; and determining the
relative magnitude of phenotypic or genomic reactivation.

infecting neurons, including viruses Which only tran
siently infect neurons.
“quiescent” or “quiescence” means the absence of detect
able infectious particles in the media and Within the

Also provided are methods to identify nucleic acid mol
ecules and/or proteins involved in virus reactivation, com

prising reactivating a quiescently-infected neural cell

cells having viral nucleic acid present in the cells.

described herein With a reactivator; and identifying nucleic

“reactivator” means a reagent Which Will cause reactiva

acid molecules and/or proteins Which are uniquely expressed

tion of quiescent virus.

during reactivation.
Also provided are methods to identify the origins of DNA

replication important to virus reactivation, comprising reac

15

“reagent” means a composition or an environmental

tivating a quiescently-infected neural cell described herein
With a reactivator; and identifying the origins of replication

condition, temperature, ultraviolet radiation,
biological, etc.

Which are uniquely associated With reactivation.
Also provided are methods to identify nucleic acid mol

“virus” means the de?nition as understood by those in the
art, as Well as viroid particles such as prions, and

ecules and/or proteins involved in establishing and main

including natural and arti?cial alterations thereof (eg.

taining virus latency, comprising establishing latency of a

mutations (eg. temperature sensitive mutations),

neural cell described herein according to the methods

including deletions, insertions, etc.)

described herein; and identifying nucleic acid molecules

and/or proteins Which are uniquely expressed during latency.

“reactivation” means any change in phenotype or geno
type from a quiescent state.

25

Also provided are methods to identify the origins of DNA

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shoWs induction of HSV-2 from QIF-PC12 cell

replication important to establishing and maintaining virus
latency, comprising establishing latency of a neural cell

cultures. Nonproductive cultures subjected to 50 pM for
skolin (A), HS (43° C., 3 h) (I, or mock-induction (O) on
day 15 pi. Parallel cultures cocultivated With Vero cells 2
days after the forskolin induction (
Y

described herein according to the methods described herein;

and identifying nucleic acid molecules and/or proteins
Which are uniquely expressed during latency.
Also provided are methods to screen an attenuated virus’

FIGS. 2A and 2B shoW the effect of cocultivation on

relative ability to be reactivated, comprising introducing a

induction of HSV-1 from QIF-PC12 cell cultures. Nonpro
ductive QIF cultures subjected to 50 pM forskolin (A), HS

reactivator to a quiescently-infected neural cell described

herein, Wherein the neurotropic virus is an attenuated virus;
and determining the relative magnitude of reactivation.

35

(43° C., 3 h) (I), or mock-induction (O) on day 15 pi.
FIG. 3 shoWs that the reactivation of HSV-2 is multiplic

Also provided are methods to determine the ability of a
virus to become quiescent and/or reactivatable in a neural

ity of infection (MOI) dependent. Nonproductive cultures
subjected to 50 pM forskolin (Y, MOI=3), (A, MOI=30), or

cell line, comprising introducing a non-neurotropic virus to

mock-induction (O) on day 15 pi.

differentiated and viable PC12 cells in a serum-free medium;

FIG. 4 shoWs the reactivation of HSV-2 from QIF-PC12
cell cultures established Without ACV. Nonproductive cul
tures subjected to 50 pM forskolin (A) or mock-induction
(O) on days 15 and 30 pi.

replenishing the serum-free medium after introduction of the

neurotropic virus to maintain acceptable cell viability.
Preferably, the medium is replenished daily for three (3)
days, and thereafter, every tWo (2) to three (3) days until

experimentation.
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All patents, patent applications and literatures cited in this
description are incorporated herein by reference in their
entirety. In the case of inconsistencies, the present

DEFINITIONS

For the purposes of the present application, the folloWing
terms shall have the folloWing meanings:

disclosure, including de?nitions, Will prevail.

a or “an”, When describing a noun, refers to one or more
of that noun.

The mechanisms that govern HSV-2 reactivation from

latency remain unknoWn. An obstacle to understanding
HSV-2 latency and reactivation has been the lack of in vitro
models that permit analysis of HSV-2 quiescence and induc

“acceptable cell viability” means suf?cient viability of
quiescently infected cells to perform experiments.
“antiviral reagent” means a reagent Which prevents viral
groWth or DNA replication in a cell.
“composition” means any compound or composition
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tion at the neuronal and clonal cell level. In a preferred

embodiment, the present invention is neurally-differentiated
cells infected With viruses in a manner that supports a

long-term nonproductive infection for experimentation.

made by any means. “Composition” includes synthetic
or naturally-occurring compounds or compositions,

Also in a preferred embodiment, the invention is directed to
a cell culture research model for HSV-2 quiescent infection
in ND-PC12 cells to investigate quiescent and reactivation
properties of HSV-2. This model represents an improvement

Whether puri?ed or not, and can include: biologicals,

chemicals, herbal extract(s); precursor(s); metabolite
(s); and ingredient(s), including enantiomer(s) of a
racemic mixture. The de?nition of “composition”
includes compounds produced in situ by virtue of an
immune response (i.e., immunoglobulins and com
pounds involved in in?ammation), as Well as
organisms, such as: viruses, bacteria and fungi.

DESCRIPTION OF THE INVENTION

of existing cell culture models for HSV-1. Advantages of the
QIF-PC12 cell culture model include: (1) establishment and
65

maintenance of a HSV-2 quiescent infection in a high
proportion of PC12 cell cultures With and Without the
transient use of ACV; (2) the ability to produce HSV-2 from

US 6,573,041 B2
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a quiescent state in response to forskolin and HS treatment

and inducible reactivation using a range of MOIs. Thereby
these enhanced features of the invention enable the analysis
of reactivation events of a cryptic HSV genome at the single
neural cell level in vitro.

incubated With an antiviral composition for approximately
?ve (5) to tWelve (12) days, more especially Wherein said
container is incubated at a temperature less than 40 degrees
Celsius (40° C.), and most especially Wherein said serum
free medium alloWs for constant cell density and imparts
neural characteristics to said cells. HoWever, those methods
Which also include a neurotropic virus selected from the

The present invention provides, inter alia, neural cells

polyoma viruses, measles viruses, human immunode?ciency

for as long as 4 Weeks post infection; and (3) the ability to

discriminate betWeen quiescence, spontaneous reactivation

group consisting essentially of varicella Zoster viruses,

comprising a PC12 cell quiescently infected With a neuro

tropic virus. Preferred quiescently-infected neural cells are
those Wherein the neurotropic virus is a neurotropic herpes
virus. More preferred are quiescently-infected neural cells
Wherein the neurotropic virus is a neurotropic human herpes
virus. More preferred are quiescently-infected neural cells
Wherein the neurotropic herpes virus is a human herpes

10

15

group consisting essentially of varicella Zoster viruses,

viruses, papillomaviruses, adenoviruses, cytomegaloviruses,
epstein barr viruses, hepatitis viruses, coronaviruses, cox
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses,
togaviruses, and rhinoviruses, are also preferred.
Certain PC12 cells are available commercially as
25

mentation. Further preferred methods are those Wherein the
neurotropic virus is a neurotropic herpes virus and still more
preferred are those methods Wherein the neurotropic herpes
virus is a human herpes simplex 2 virus. HoWever, those
methods Which also include a neurotropic virus selected
from the group consisting essentially of varicella Zoster

viruses, polyoma viruses, measles viruses, human immuno

obtained from American Type Culture Collection (ATCC,

de?ciency viruses, papillomaviruses, adenoviruses,
cytomegaloviruses, epstein barr viruses, hepatitis viruses,

Rockville, Md.) or other commercial entities. These cells are
Within the scope of the present invention as Well. There are

coronaviruses, coxsackie viruses, rabies viruses,
?aviviruses, paramyxoviruses, togaviruses, and rhinoviruses

eight (8) types of herpes virus. For instance, human herpes
virus 1, human herpes virus 2, human herpes virus 6, human

are also preferred.

herpes virus 7, and human herpes viruses 8 are “types” of
human herpes virus. Within the meaning of each of the
35

The methods described herein may utiliZe the speci?c
conditions described in the examples, but may also vary
therefrom. Variations include the use of collagen in the

plating technique; collagen need not be used, but ef?ciency
Will be improved if it is. Moreover, the plates need not be as
con?ning as described in the examples; other surfaces,
including different shapes and siZes, can be used, so long as

instance, human HSV-2 includes the strains listed in the
examples, as Well as these other strains, such as G and 333
HSV-2 strains.
Viruses can be obtained by purchasing them commer
cially (as part of a cell line or tissue sample) from ATCC or

a viable cell culture can be maintained for the length of time
desired. The multiplicity of infection may be from 0.5 to

greater than 15, although the examples describe preferred
higher multiplicities for HSV-2 When high reactivation rates

by obtaining them according to the procedures Well knoWn
45

Knipe, Fundamental Virology; Luria et al, General Virology;
and Fenner et al., Molecular Virology. The present
quiescently-infected neural cells can be made by the meth
ods disclosed herein.
Particularly useful in the preparation of the neural cells
are the examples, although variations as described herein

Will also produce the present materials. Moreover, certain
reasonable optimiZation of the methods can be accomplished

neurally-differentiated and viable PC12 cells in a serum-free

replenished daily for three (3) days after introduction of the
neurotropic virus to the neurally-differentiated PC12 cells,
and thereafter, every tWo (2) to three (3) days until experi

polyoma viruses, measles viruses, human immunode?ciency

in the art, such as by obtaining clinical isolates, or cultures
from researchers in the ?eld. Textbooks Which discuss
manipulations of viruses are many, including: Fields &

Another such method of establishing quiescently-infected
neural cells comprises introducing neurotropic virus to
medium, and replacing the serum-free culture medium With
fresh serum-free media to maintain acceptable neurally
differentiated cell’s viability. Preferably the culture media is

cells Wherein the neurotropic virus is selected from the

viruses listed in the claims are several hundreds of “strains”
of those viruses. The strains of each virus type are, of course,
included Within the scope of the present invention. For

epstein barr viruses, hepatitis viruses, coronaviruses, cox
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses,
togaviruses, and rhinoviruses are also preferred.

simplex 2 virus. HoWever, those quiescently-infected neural

described in the examples. PC12 cell variants are Within the
scope of the present invention, as are any cells derived from
the neural crest. These materials can be commercially

viruses, papillomaviruses, adenoviruses, cytomegaloviruses,

are desired. HoWever, in certain instances, it may be optimal
to have loW reactivation rates, depending on the particular
use of the neural cells. In that case, loWer multiplicities
Would be optimal. The antiviral reagent used can be any
Which causes quiescence of the neurotropic virus. The

exempli?ed reagent, acycloguanosine, may be optimiZed
chemically for this purpose, or other antivirals may be used.

For example, Zidovudine (AZT), lamivudine (3TC) indi

navir (IDV), ganciclovir, famiciclovir, foscarnet,
idoxyuridine, phosphoacetic acid, 5-?uorouracil, or similar
55

compounds and analogs thereof may be used. The concen
trations of the compound used to cause quiescence can also

according to methods Well-known in the art.

be modi?ed as necessary. Moreover, a combination (eg. tWo

In addition, a signi?cant aspect of this invention provides
the methods of establishing quiescently-infected neural
cells. One such method comprises introducing a neurotropic

or more) of antiviral drugs may be used. Incubation of the
PC12 cells With the antiviral is optimally that described in
the examples, but can be more or less, depending on the

virus to neurally-differentiated and viable PC12 cells in a

particular reagent used. OptimiZation of the incubation

serum-free medium, said differentiated PC12 cells being in

schedule is Within the skill of the art. Lastly, the media used

a container; and incubating said container With an antiviral
reagent for a time necessary to accomplish quiescence of

can be any that alloWs viable cell groWth, so long as it alloWs

viral activity; and removing said antiviral agent from said
container. Preferred methods comprise human herpes sim
plex 2 virus as the neurotropic herpes virus and acyclovir as
the antiviral agent, especially Wherein said container is

or virus in order to transiently inhibit viral groWth. It is
optimal to change the media as described in the examples,

for constant cell density and may be supplemented reagent
65

but it is not necessary, so long as the cells are acceptably

viable.
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Also provided are methods of reactivating a quiescent
virus from neural cell, comprising: introducing a reactivator

containing medium, replacing the serum-free medium With
fresh serum-free, test reagent-containing medium after intro
duction of the non-neurotropic virus to the differentiated
PC12 cells to maintain acceptable differentiated PC12 cell

to a quiescently-infected neural cell described herein. This

aspect of the invention is particularly useful in studying

viability. Preferably, the media is replenished daily for three
(3), and thereafter, every tWo (2) to three (3) days. The

reactivation, as Well as in studying quiescence. The infor

mation gleaned from reactivation and quiescence studies
Will be of bene?t in drug discovery. The preferred

preferred neural cells for use in this embodiment are those

are those comprising neurotropic herpes viruses, preferably

Which are neurotropic herpes viruses, speci?cally HSV-2.
Also provided are methods for eliciting phenotypic

HSV-Z. The neural cells can be prepared as described herein

change in a neural cell, introducing a reactivator to a

quiescently-infected neural cells for use in this embodiment

and introducing a reactivator can be accomplished according

quiescently-infected neural cell described herein, and elic

by any means Which causes reactivation.

iting a phenotypic change in said neural cell. Preferred are

such methods Wherein said phenotypic change is selected

Also provided are methods for determining the ability of
a test reagent to suppress virus reactivation from a

quiescently-infected neural cell, comprising, introducing a

15

test reagent to a quiescently-infected neural cell described
herein; and introducing to said neural cell a reactivator; and

determining if reactivation has been suppressed. This aspect
of the invention is particularly useful for identifying poten
tial anti-viral drugs. The preferred quiescently-infected neu
ral cells for use in this embodiment are those comprising

neurotropic herpes viruses, preferably HSV-Z. The neural
cells can be prepared as described herein; introducing a
reactivator can be accomplished by any means Which causes
reactivation; and determining reactivation can be accom

25

plished by any means, including, for example, those means
described in the examples, or other Well-known means.

from the group consisting of synthesis of myelin, synthesis
of neurotransmitter, degradation of neurotransmitters, cell
death, and viral shedding. This aspect of the invention is
particularly useful in studying disease states, such as mul
tiple sclerosis, or other neuron-associated diseases. The
neural cells can be directed via molecular techniques, for
example, to result in disease state upon activation.
Alternatively, the neural cells can be directed to be positive
in?uences on the environment, such that gene therapy stud
ies Will be possible using this embodiment. In all aspects of
the present embodiment, the methods Will be useful for drug
discovery in that the mechanisms of phenotypic change can
be studied. The preferred quiescently-infected neural cells
for use in this embodiment are those comprising neurotropic

herpes viruses, preferably HSV-Z.

Also provided are methods for determining the ability of

Also provided are methods for determining the suscepti

a test reagent to induce virus reactivation from a neural cell,

comprising introducing a test reagent to a quiescently

bility of a person infected With a quiescent virus to reacti

infected neural cell described herein; and determining if
reactivation has been induced. This aspect of the invention

vation by a reagent, comprising introducing a reactivator to
a quiescently-infected neural cell described herein, Wherein

is particularly useful for identifying potential reactivators. In

the neurotropic virus is a strain isolated from a person

as a drug (or potential drug), vaccine, carrier, food, or

infected With said neurotropic virus; and determining the
relative magnitude of phenotypic or genomic reactivation.
This aspect of the present invention is particularly useful for

environmental condition is implicated through the use of this
method as a reactivator of quiescent virus, it Would be

patient diagnosis and directed medical care. Since some
strains are more reactivatable than others are, it is important

advisable for an infected individual to avoid the reagent,

to determine the aggressiveness and/or timing of treatment.
The present embodiment, for example, can identify those
individuals Who harbor a strain particularly reactivatable by

one aspect, this embodiment is useful in drug discovery as
part of a toxicology screen. For example, if a reagent such

35

since reactivation of virus is normally detrimental to the

individual. The preferred quiescently-infected neural cells
for use in this embodiment are those comprising neurotropic

sunlight, in Which those patients could use sunscreen or
avoid the sun. The method Would provide information to
patients Who have a less reactivatable strain, so that sup

herpes viruses, preferably HSV-Z. The neural cells can be
prepared as described herein; introducing a test compound

can be accomplished by any means Which causes interaction 45 pressor drug levels can be loWered in comparison to those

betWeen the test compound and the neural cells; and deter
mining reactivation can be accomplished by any means,
including, for example, those means described in the

Who have a highly reactivatable strain. The preferred
quiescently-infected neural cells for use in this embodiment

examples, or other Well-known means.
Also provided are methods to determine a reagent’s

HSV-2.
Also provided are methods to determine the ability of a

ability to inhibit establishment of a viral infection, compris
ing introducing a virus to differentiated and viable PC12
cells in a serum-free, test reagent-containing medium, said
differentiated PC12 cells being in a container; and incubat
ing said container With an antiviral reagent for a time

non-neurotropic virus to become quiescent and/or reactivat

are those comprising neurotropic herpes viruses, preferably

55

necessary to accomplish quiescence of viral activity in the
absence of said test reagent; and removing said antiviral
agent from said container; and determining said test
reagent’s ability to inhibit quiescence. This aspect of the
invention is particularly useful for identifying reagents

able in a neural cell line, comprising introducing a non
neurotropic virus to differentiated and viable PC12 cells in
a serum-free medium, said differentiated PC12 cells being in
a container; and incubating said container With an antiviral
reagent for a time necessary to accomplish quiescence of

viral activity; and removing said antiviral agent from said

container; and determining said non-neurotropic virus’s
ability to become quiescent and or reactivatable. In addition,
methods are provided to determine the ability of a non

Which could be used as an anti-viral drug. The reagents

neurotropic virus to become quiescent and/or reactivatable

identi?ed as inhibiting the establishment of quiescence
Would be particularly effective to administer during the ?rst
lytic phase of a viral infection. Additionally, methods to

in a neural cell line, comprising introducing a non
neurotropic virus to differentiated and viable PC12 cells in

determine a reagent’s ability to inhibit establishment of a

viral infection, comprise introducing a virus to differentiated
and viable PC12 cells in a serum-free, test reagent

65

a serum-free medium, said serum-free medium being replen
ished With fresh serum-free media to maintain acceptable

differentiated PC12 cell viability. Preferably the media is
changed daily for the ?rst three (3) days after introduction of
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the non-neurotropic virus, and thereafter every tWo (2) to
three (3) days. This aspect of the present invention is
particularly useful to identify additional viruses Which may
be amenable to the present invention. The preferred

ity and express genes encoding neuronal cell-speci?c pro
teins (Green and Tischler 1976; Green and Tischler 1982).

quiescently-infected neural cells for use in this embodiment

virus (eg., human herpes virus) under conditions that restrict
viral propagation. A de?ned regimen of media changes is

Cells are maintained in serum-free medium to render them

non-dividing. Next, cells are inoculated With neurotropic

are those comprising neurotropic herpes viruses, preferably

used to establish a quiescent and nonproductive state fol
loWing the WithdraWal of the antiviral treatment. Evidence
of establishment of a quiescent and persistent infection
comes from assays demonstrating that cells survive the
infection, a nonproductive viral state is established in the

HSV-2.

Also provided are methods to identify nucleic acid mol
ecules and/or proteins involved in virus reactivation, com

prising reactivating a quiescently-infected neural cell
described herein With a reactivator; and identifying nucleic

majority of cultures, and cells support spontaneous and
inducible virus production.

acid molecules and/or proteins Which are uniquely expressed
during reactivation. This aspect of the present invention is
particularly useful for general scienti?c research or to study

possible targets for drug discovery. The preferred

EXAMPLE 2

15

quiescently-infected neural cells for use in this embodiment

Morphologic Differentiation

are those comprising neurotropic herpes viruses, preferably

For morphologic differentiation, PC12 cells Were main
tained in RPMI 1640 supplemented 0.1% bovine serum

HSV-2.

Also provided are methods to identify the origins of DNA

albumin, fraction V (BSA) and 50 ng/ml of 2.5S mouse

replication important to virus reactivation, comprising reac

nerve groWth nerve factor (NGF) (Becton Dickinson)

tivating a quiescently-infected neural cell described herein
With a reactivator; and identifying the origins of replication

(maintenance media) throughout the studies, unless

Which are uniquely associated With reactivation. This aspect

of the present invention is particularly useful for general
scienti?c research or to study possible targets for drug

25

discovery. The preferred quiescently-infected neural cells
for use in this embodiment are those comprising neurotropic

indicated, beginning on the day of plating. PC12 Were
plated, folloWing tWo rinses With RPMI 1640 containing
0.1% BSA and dissociation by passage through a 22-gauge
needle, in 12-Well tissue culture dishes (Bector Dickinson
LabWare, Franklin Lakes, N.J., USA) coated With rat tail

collagen type 1 (Bector Dickinson) at 1.1><105 cells/Well in

herpes viruses, preferably HSV-2.

maintenance media. Collagen Was applied as recommended

Also provided are methods to screen an attenuated virus’

by the supplier. FolloWing 4 days of differentiation in

relative ability to be reactivated, comprising introducing a

maintenance media, cultures Were maintained in RPMI 1640

reactivator to a quiescently-infected neural cell described

supplemented With 10% horse serum (heat-inactivated) and

herein, Wherein the neurotropic virus is an attenuated virus;
and determining the relative magnitude of reactivation. This
aspect of the invention is particularly useful to determine the
reactivatability of potential or actual vaccines. Vaccines

cultures received maintenance media supplemented With

5% FBS, and 50 ng/ml NGF for 2 days. The folloWing day
35

Which can reactivate, Whether alone, or in combination With

100 pM acycloguanosine (ACV) When indicated, purchased
from Sigma (St. Louis, Mo., USA). Morphologic differen
tiation Was con?rmed by microscopic visualiZation of den
dritic processes. Media Was changed every 2 to 3 days unless
indicated.

an additional reagent, Would be potentially dangerous. In
other Words, this aspect of the invention can be used a

specially-designed toxicology assay. The preferred
EXAMPLE 3

quiescently-infected neural cells for use in this embodiment

are those comprising neurotropic herpes viruses, preferably

Establishment of a Quiescent Infection

HSV-2.

ND-PC12 cells Were infected in a volume of 0.4 ml/Well

EXAMPLE 1

in 12-Well plates Without agitation at the indicated multi
45

Virus and Cells

ACV Was maintained in the medium from 1 day prior to

infection 8 days post-infection

Rat pheochromocytoma (PC12) and Vero (Africa green
monkey kidney) cells Were obtained from ATCC (Rockville,

After ACV WithdraWal,

a quiescent state (i.e., free of detectable infectious virus in
culture supernatants) Was maintained for at least 7 days prior

Md., USA). All culture media and supplements Were pur

to induction. At the indicated times, Vero cells Were

chased from Gibco BRL (Gaithersburg, Md., USA) unless

trypsiniZed, Washed tWice With RPMI and introduced into

otherWise indicated. PC12 cells Were groWn in RPMI 1640

the QIF-PC12 cell cultures at a ratio of 1:1 in maintenance
media.

media containing 5% fetal bovine serum (FBS) and 10%
heat-inactivated horse serum. Vero cells Were groWn and

maintained in M199 medium containing 5% FBS. Cells

plicity of infection (MOI) overnight at 37° C. When used,

EXAMPLE 4

55

Were incubated at 37° C. in humidi?ed incubator With 5%

Induction Stimuli and Assay of Virus Production

CO2. All media Was supplemented With penicillin (100
units/ml) an (streptomycin (100 pig/ml). HSV-2 strain 333

HSV QIF-PC12 cells, that Were free of detectable infec
tious virus, Were subjected to heat stress (43° C. for 3 h in

Was a kind gift from Philip R Krause (Food and Drug

Administration, Bethesda, Md., USA). Viral stocks Were

an incubator), or maintenance media supplemented With or

prepared in Vero cells and maintained at —85° C.

Without 50 pM forskolin (Sigma) as previously described
(Danaher et al, 1999a,b). Virus production Was determined
using 25% volume of supernatants from infected PC12
cultures in a direct plaque assay (DPA) on monolayers of
Vero cells as previously described (Miller and Smith, 1991).
Cultures Were subsequently replenished With fresh mainte

In particular, the neuronally-differentiated PC12 cells
Were established from pheochromocytoma of rat adrenal
medulla, and used to host a persistent viral infection. Neural

differentiation of the PC12 cells comprises groWing cells in
de?ned medium containing nerve groWth factor. Under these
conditions cells extend neurites, develop electrical excitabil

65

nance media.
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EXAMPLE 5

cell cultures Were established With HSV-1 strain 17+ at MOI
of 1 With the transient use of ACV as described in the
Material and methods. Cultures Were either mock coculti
vated (A), or cocultivated With Vero cells at a 1:1 ratio 3

HSV-2 Establishes a Quiescent Infection in ND
PC12 Cells That is Reversible.

days before induction
Nonproductive QIF cultures Were
subjected to 50 pM forskolin, HS (43° C., 3 h), or mock

Preliminary data indicated that QIF-PC12 cell cultures
established With HSV-2 produce virus following heat stress
and forskolin and forskolin induction (data not shoWn).

induction on day 15 pi. Cultures Were monitored for virus

production using culture supernatants in the direct plaque

HoWever, unlike previous ?ndings With HSV-1, minimal
amounts of virus (i.e., only a single plaque forming unit)

assay. Virus Was detected in 0% (0/72) mock cocultivated

and 1.7% (1/60) Vero cocultivated cultures betWeen the day
of ACV WithdraWal (day 8 pi.) and day of induction.
Therefore, the ?ndings from these tWo experiments dem

Were detected in the majority of QIF-PC12 cell cultures

determined to be positive for HSV-2 production folloWing
induction. Furthermore, cocultivation of HSV-2 established
QIF-PC12 cell cultures With Vero cells did not increase the

proportion of cultures producing virus, but increased the
amount of virus detected from such cultures. This indicated
that HSV-2 Was not induced from QIF-PC-12 cell cultures

onstrate that cocultivation With Vero cells did not contribute
to the reactivation response. Furthermore, HSV-1 and -2
15 established QIF-PC12 cell cultures can maintain a non

productive state in the presence of Vero cells. This indicates
that loW amounts of infectious virus are not being chroni

by cocultivation With Vero cells, and Vero cells could be
used to increase the sensitivity of the system.
Based on these ?ndings, forskolin and HS induced HSV-2
reactivation from QIF-PC12 cell cultures that Were coculti
vated With Vero cells Was analyZed in more detail. QIF
PC12 cell cultures Were established With strain 333 at MOI
of 10 as described in the Materials and methods using
transient ACV treatment. Cultures Were cocultivated With
Vero cells at a ratio of 1:1 three days before induction With

cally shed and the cultures are truly quiescent.
EXAMPLE 6

Long-Term HSV-2 Quiescent Infection in PC12
Cells Cocultivated With Vero Cells
25

forskolin or HS (day 15 p.i.). Virus production Was moni
tored from day 10 through 23 pi. Prior to induction, HSV-2
Was detected infrequently (2.8%; 1/36) in cocultivated cul

lished With HSV-2 as described above. Cultures Were coc

ultivated With Vero cells at a ratio of 1:1 Within 10 days of
AC WithdraWal. Induction Was performed With forskolin on

tures. The 35 cultures that Were not shedding virus Were used

in induction assays. FolloWing induction treatment (FIG. 1),

day 30 pi. Cultures Were monitored for virus production
using culture supernatants. Over the 3 Week period betWeen
ACV WithdraWal and induction, 71% (17/24) of the HSV-2

virus Was detected in 90 to 100% of HS and forskolin

induced cocultivated cultures, and 8.3% (1/12) of mock
induced cocultivated cultures. These data indicate that qui
escently infected cultures can be established With HSV-2 and

virus production can be induced by both physical and

35

Were cocultivated With Vero cells 2 days after induction With

skolin 30 days p.i.

forskolin. This alloWed for comparison of virus production
occurring before and after cocultivation. Second, induction

EXAMPLE 7
45

Reactivation of HSV-2 is MOI Dependent
Next, it Was determined Whether the ef?ciency of HSV-2
activation from quiescence Was MOI-dependent. QIF-PC12

cells (Danaher et al, 1999a). QIF-PC12 cell cultures Were
established With HSV-2 strain 333 at MOT of 10 With the
transient use of ACV as described in the Material and

cell cultures Were established With HSV-2 strain 333 at
MOIs of 3 and 30 and cocultivated With Vero cells at a ratio

methods. Cultures Were cocultivated With Vero cells at a 1:1

ratio 3 days before induction. Nonproductive cultures Were

of 1:1 on day 12 pi. as above. Nonproductive cultures
harboring a quiescent infection on day 15 pi. Were subjected
to forskolin (50 pM) or mock induction. Virus production

subjected to 50 pM forskolin, HS (43° C., 3 h), or mock
induction on day 15 pi. Cultures Were monitored for virus

production using culture supernatants in the direct plaque

Was monitored using cultured supernatants as described
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ultivated before induction and 0% (0/12) of cultures cocul
tivated after induction betWeen day of ACV WithdraWal (day
8 pi.) and day of induction. In HSV-2 established cultures
(FIG. 1), virus Was detected in a similar proportion of
cultures by day 4 post-forskolin treatment Whether cultures

above. BetWeen the period of ACV WithdraWal and
induction, virus Was detected in 4.2% (1/24) of cultures for
each MOI. FIG. 3 shoWs that viral MOI in?uenced the

ef?ciency of HSV-2 activation from quiescence. Cultures
infected at MOI of 30 activated virus at a higher rate (i.e.,

1—2 days faster) and degree (100%; 12/12 by day 6) in
response to forskolin, than cultures infected at MOI of 3

Were cocultivated before or after induction.

(82%; 9/11 by day 7).

This indicated that the Vero cells did not contribute to

induction of HSV-2, but merely alloWed for detection of
progeny virus. Results shoWn in FIG. 2 demonstrate that
cocultivation of HSV-1 established QIF-PC12 cell cultures
With Vero cells did not induce HSV-1 production or alter the
ef?ciency of the response to forskolin and HS. QIF-PC 12

duced from 100% (8/8) of forskolin induced cultures and 0%
quiescence can be maintained in QIF-PC12 cell cultures in
the presence of Vero cell cocultivation and absence of ACV,
and these cultures reactivate virus When induced With for

First, parallel neuronal cultures established With HSV-2

assay. Virus Was detected in 2.8%; (1/36) of cultures coc

infected culture maintained quiescence. HSV-2 Was pro

(0/9) of mock induced cultures by 8 days post-induction
(data not shoWn). These data indicate that long-term HSV

chemical stimuli.
The possibility that Vero cells in?uenced HSV induction
from QIF-PC12 cell cultures Was assessed in tWo Ways.

of HSV-1 established cultures Was analyZed in the presence
and absence of Vero cell cocultivation, as detection of
HSV-1 progeny from such cultures does not require Vero

The ability of HSV-2 to maintain a short-term quiescent
infection in ND-PC12 cells suggested such a state could be
maintained long-term in the presence of Vero cell coculti
vation. To assess this, QIF-PC12 cell cultures Were estab
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In the mock-induced QIF-PC12 control cultures, sponta
neous virus production Was not detected (0%; 0/11, 0/12) at
either MOI. These data indicate that the ef?ciency of for
skolin induced HSV-2 activation from QIF-PC12 cell cul
tures is MOI-dependent. Moreover, QIF-PC12 cell cultures

US 6,573,041 B2
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established With ACV at higher MOI yielded HSV-2 sooner

Croen K D, Ostrove J M, Dragovic L, Straus E (1991).
CharacteriZation of herpes simpleX virus type 2 latency
associated transcription in human sacral ganglia and in

and from a higher proportion of cultures following induction
than those established at a loWer MOI. A majority of these
cultures maintained HSV-2 in a quiescent state for at least 30
days and virus Was inducible thereafter With forskolin.
EXAMPLE 8

cell culture. J Infect Dis 163: 23—28.
Danaher R J, Jacob R J, Miller C S (1999a). Establishment
of a quiescent herpes simpleX virus type 1 infection in
neurally-differentiated PC12 cells. J Neuro Wrol 5:

ACV is Not Required for the Establishment of a
Quiescent Infection With HSV-2

258—267.
Danaher R J, Jacob R J, Chorak M D, Freeman C S, Miller
C S (1999b). Heat stress induces reactivation of herpes

10

Since HSV-2 Was found to be non-permissive in ND-PC
to establish a quiescent infection Without the use of ACV.
QIF-PC12 cell cultures Were established With HSV-2 strain

333 in the absence of ACV in parallel to the above experi

15

ment. Cultures Were cocultivated With Vera cells at a ratio of

1:1 on day 12 pi. Nonproductive cultures Were subjected to
50 nM forskolin or mock-induction on days 15 and 30 pi.
Cultures Were monitored for virus production by direct
plaque assay of supernatants. Virus Was detected in 3/24
induction. Following infection, the culture media Was

Harris R A, Preston C M (1991). Establishment of latency in
vitro by the herpes simpleX virus type 1 mutant in 1814.

changed daily for 3 days pi. and thereafter every 2 to 3 days

J Gen Virol 72:907—913.
25

3 (88%, 21/24) and 30 (79%, 19/24) until the day of
induction (day 15 pi.) FIG. 4 shoWs that HSV-2 Was
produced from 91% (10/11) of forskolin induced and 10%
(1/ 10) of mock induced cultures established at MCI of 3 by
day 6 post-induction. Parallel cultures established at MCI of

Hill T J, Field H J, Roome AP C (1972). IntraXonal location
of herpes simpleX virus particles. J Gen Virol 15 :253—257.
Kieff E D, Bachenheimer S L, RoiZman B (1971). SiZe,
composition, and structure of the deoXyribonucleic acid
of herpes simplex virus subtypes 1 and 2. J Viral
8:125—132.

Kieff E, Hoyer B, Bachenheimer S. RoiZman B (1972).
Genetic relatedness of type 1 and type 2 herpes simpleX

30 demonstrated a similar level of forskolin induced reac

tivation (90%, 9/ 10) and slightly higher (22%, 2/9) sponta

viruses. J Viral 9:738—745.

neous virus production than cultures established at MOI of

3 (data not shoWn). In addition, the mock induced MOI of
3 cultures that Were non-productive on day 23 Were main 35
tained for an additional 7 days, and on day 30 pi. Were mock
or forskolin induced. Virus Was recovered from 100% (4/4)

of forskolin induced cultures and 0% (0/4) of mock induced

Kondo Y, Yura Y, Iga H, YanagaWa T, Yoshida H. Furumoto
N, Sato M (1990). Effect of heXamethylene bisacetamide
and cyclosporin A on recovery of herpes simpleX virus
type 2 from the in vitro model of latency in a human
neuroblastoma cell line. Cancer Res 50:7852—7857.

Krause P R, Stanberry L R, Bourne N, Connelly B,
KuraWadWala J F, Patel A, Straus S E (1995). EXpression
of the herpes simpleX virus type 2 latency-associated
transcript enhances spontaneous reactivation of genital
herpes in latently infected guinea pigs. J Exp Med

cultures. These data indicate that HSV-2 can establish a

long-term (i.e., 30 days) quiescent state in ND-PC12 cell
cultures Without the use of ACV, and virus reactivation
results from forskolin induction.

181:297—306.
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12. The method of claim 11, Wherein the antiviral reagent
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What is claimed is:
1. APC12 cell quiescently infected With a human herpes

phosphoacetic acid, 5-?uorouracil, and analogs thereof.
13. The method of claim 12, Wherein said container is
55

incubated With acycloguanosine for approximately ?ve (5)
to tWelve (12) days.
14. The method of claim 13, Wherein said container is
incubated at a temperature less than 40 degrees Celsius (40°

simplex 2 virus (HSV-2).

C.).

2. A method of reactivating a quiescent virus from at least

one quiescently-infected PC12 cell, comprising, introducing

15. The method of claim 11, Wherein said serum-free
medium alloWs for constant cell density and imparts neural

a reactivator to a cell of claim 1.

characteristics to said cells.

3. A method for determining the ability of a test reagent

16. A method of establishing quiescently-infected PC12

cells, comprising:

to suppress virus reactivation from a quiescently-infected

PC12 cell of claim 1, comprising:
a) introducing a test reagent to said PC12 cell; and
b) introducing to said PC12 cell a reactivator; and

c) determining if reactivation has been suppressed.

a) introducing an HSV-2 virus to neurally-differentiated
65

and viable PC12 cells in a serum-free medium; and

b) replenishing the serum-free medium after introducing
the virus to maintain acceptable cell viability.
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17. A method of claim 16 wherein the medium is replen
ished daily for 3 days and thereafter every tWo (2) to three

proteins involved in maintaining virus quiescence, compris

(3) days until experimentation.

mg:

20. A method to identify nucleic acid molecules and/or

a) establishing quiescence according to claims 11 or 16;

18. A method to identify nucleic acid molecules and/or

proteins involved in establishing virus quiescence, compris

5

ing:

Which are uniquely expressed during maintenance of

a) establishing quiescence according to claims 11 or 16;

quiescence.

and

21. A method to identify the origins of DNA replication

important to maintaining virus quiescence, comprising:

b) identifying nucleic acid molecules and/or proteins

a) establishing quiescence according to claims 11 or 16;

Which are uniquely expressed during establishment of

and

quiescence.

b) identifying the origins of replication Which are

19. A method to identify the origins of DNA replication

uniquely associated With maintaining quiescence.

important to establishing virus quiescence, comprising:
a) establishing quiescence according to claims 11 or 16;
and

and

b) identifying nucleic acid molecules and/or proteins

15

22. A method of claim 21 Wherein the medium is replen
ished daily for 3 days and thereafter every tWo (2) to three

(3) days until experimentation.

b) identifying the origins of replication Which are

uniquely associated With establishing quiescence.
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